Edwards Lifesciences Corp (EW) has been the focus of several recent analyst reports and investment moves. Notably, the company's Q3 2025 earnings call highlighted
strong revenue growth. Several banks and financial firms adjusted their holdings in EW - Huntington National Bank, Bank of New York Mellon Corp, and PKO Investment Management Joint Stock Co reduced their stake, while Burney Co., Telos Capital Management, and Machina Capital S.A.S. acquired new shares. Several
analysts maintained their ratings for EW, with firms like Truist Securities, Canaccord Genuity, and Stifel holding steady while Jefferies upgraded the corporation. Other notable news include EW's
ALTERRA study potentially transforming heart valve treatment and Edwards Lifesciences unveiling its CFO transition plan. Despite some valuation concerns over margin decline, EW showcased
robust Q2 earnings driven by TMTT growth and updated guidelines for treating severe aorticstenosis. The company also received price target raises from several analysis firms including RBC Capital, Barclays, Citigroup, and Goldman Sachs.
Edwards Lifesciences Corp EW News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Thu, 06 Nov 2025 10:07:29 GMT -
Rating 8
- Innovation 4
- Information 6
- Rumor -5
